G C Prendergast

Summary

Publications

  1. ncbi request reprint Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer
    George C Prendergast
    Lankenau Institute for Medical Research LIMR, 100 Lancaster Avenue, Wynnewood, PA, 19096, USA
    Cancer Immunol Immunother 63:721-35. 2014
  2. ncbi request reprint Chasing cancer: from genes to drugs
    George C Prendergast
    Lankenau Institute for Medical Research, Wynnewood, Pennsylvania 19096, USA
    Cancer Biol Ther 4:901-5. 2005
  3. doi request reprint Immune escape as a fundamental trait of cancer: focus on IDO
    G C Prendergast
    Lankenau Institute for Medical Research, Wynnewood, PA 19096, USA
    Oncogene 27:3889-900. 2008
  4. pmc BAR the door: cancer suppression by amphiphysin-like genes
    George C Prendergast
    Lankenau Institute for Medical Research, Wynnewood PA, USA
    Biochim Biophys Acta 1795:25-36. 2009
  5. pmc Towards a genetic definition of cancer-associated inflammation: role of the IDO pathway
    George C Prendergast
    Lankenau Institute for Medical Research, Wynnewood, PA 19096, USA
    Am J Pathol 176:2082-7. 2010
  6. ncbi request reprint Indoleamine 2,3-dioxygenase as a modifier of pathogenic inflammation in cancer and other inflammation-associated diseases
    G C Prendergast
    Lankenau Institute for Medical Research, Wynnewood, PA 19096, USA
    Curr Med Chem 18:2257-62. 2011
  7. ncbi request reprint The c-Myc-interacting adaptor protein Bin1 activates a caspase-independent cell death program
    K Elliott
    The Wistar Institute, Philadelphia, PA, USA
    Oncogene 19:4669-84. 2000
  8. ncbi request reprint RhoB in cancer suppression
    M Huang
    Lankenau Institute for Medical Research, Jefferson Medical School, Thomas Jefferson University, Philadelphia, PA, USA
    Histol Histopathol 21:213-8. 2006
  9. ncbi request reprint RhoB facilitates c-Myc turnover by supporting efficient nuclear accumulation of GSK-3
    M Huang
    Lankenau Institute for Medical Research, Wynnewood, PA 19096, USA
    Oncogene 25:1281-9. 2006
  10. ncbi request reprint Losses of the tumor suppressor BIN1 in breast carcinoma are frequent and reflect deficits in programmed cell death capacity
    K Ge
    The Wistar Institute, Philadelphia, PA, USA
    Int J Cancer 85:376-83. 2000

Collaborators

  • Alexander J Muller
  • M Huang
  • Sunil Thomas
  • W Du
  • C Reynolds
  • MEENHARD I HERLYN
  • Courtney Smith
  • David Munn
  • K Ge
  • D Sakamuro
  • J Duhadaway
  • A X Liu
  • J B DuHadaway
  • R Wechsler-Reya
  • T Banerjee
  • N C Mao
  • J P Liu
  • K Elliott
  • E Sutanto-Ward
  • P Gaspari
  • A L Mellor
  • W P Malachowski
  • R J Wechsler-Reya
  • D E Jensen
  • K J Elliott
  • D Negorev
  • D L Ewert
  • N Rane
  • F Minhas
  • P Nelson
  • J Tomaszewski
  • R Buccafusca
  • T M Jessell
  • D Wilson
  • S B Malkowicz
  • N G Copeland
  • N A Jenkins
  • E Steingrimsson
  • J C Ruiz
  • U Rodeck
  • W Wasserman
  • S L Berger
  • K D Wilkinson
  • G G Maul
  • N Tommerup
  • Y Sekido
  • F J Rauscher
  • L A Chodosh
  • H P Gardner
  • A Borodovsky
  • H Vissing
  • J Minna
  • D C Schultz
  • S I Ha
  • N Barlev
  • A M Ishov
  • S T Marquis
  • M Proctor
  • J Zhang
  • D Simon
  • H Riethman

Detail Information

Publications29

  1. ncbi request reprint Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer
    George C Prendergast
    Lankenau Institute for Medical Research LIMR, 100 Lancaster Avenue, Wynnewood, PA, 19096, USA
    Cancer Immunol Immunother 63:721-35. 2014
    ....
  2. ncbi request reprint Chasing cancer: from genes to drugs
    George C Prendergast
    Lankenau Institute for Medical Research, Wynnewood, Pennsylvania 19096, USA
    Cancer Biol Ther 4:901-5. 2005
  3. doi request reprint Immune escape as a fundamental trait of cancer: focus on IDO
    G C Prendergast
    Lankenau Institute for Medical Research, Wynnewood, PA 19096, USA
    Oncogene 27:3889-900. 2008
    ..New modalities in this area offer promising ways to broaden the combinatorial attack on advanced cancers, where immune escape mechanisms likely provide pivotal support...
  4. pmc BAR the door: cancer suppression by amphiphysin-like genes
    George C Prendergast
    Lankenau Institute for Medical Research, Wynnewood PA, USA
    Biochim Biophys Acta 1795:25-36. 2009
    ....
  5. pmc Towards a genetic definition of cancer-associated inflammation: role of the IDO pathway
    George C Prendergast
    Lankenau Institute for Medical Research, Wynnewood, PA 19096, USA
    Am J Pathol 176:2082-7. 2010
    ....
  6. ncbi request reprint Indoleamine 2,3-dioxygenase as a modifier of pathogenic inflammation in cancer and other inflammation-associated diseases
    G C Prendergast
    Lankenau Institute for Medical Research, Wynnewood, PA 19096, USA
    Curr Med Chem 18:2257-62. 2011
    ..We propose that IDO induction in a chronically inflamed tissue may shape the inflammatory state to support, or in some cases retard, pathogenesis and disease severity...
  7. ncbi request reprint The c-Myc-interacting adaptor protein Bin1 activates a caspase-independent cell death program
    K Elliott
    The Wistar Institute, Philadelphia, PA, USA
    Oncogene 19:4669-84. 2000
    ..Our findings suggest that the tumor suppressor activity of Bin1 reflects engagement of a unique cell death program. We propose that loss of Bin1 may promote malignancy by blunting death penalties associated with oncogene activation...
  8. ncbi request reprint RhoB in cancer suppression
    M Huang
    Lankenau Institute for Medical Research, Jefferson Medical School, Thomas Jefferson University, Philadelphia, PA, USA
    Histol Histopathol 21:213-8. 2006
    ..How RhoB acts to suppress different aspects of cancer pathophysiology has emerged as a question of significant interest...
  9. ncbi request reprint RhoB facilitates c-Myc turnover by supporting efficient nuclear accumulation of GSK-3
    M Huang
    Lankenau Institute for Medical Research, Wynnewood, PA 19096, USA
    Oncogene 25:1281-9. 2006
    ..The ability of RhoB to support GSK-3-dependent turnover of c-Myc offers a mechanism by which RhoB acts to limit the proliferation of neoplastically transformed cells...
  10. ncbi request reprint Losses of the tumor suppressor BIN1 in breast carcinoma are frequent and reflect deficits in programmed cell death capacity
    K Ge
    The Wistar Institute, Philadelphia, PA, USA
    Int J Cancer 85:376-83. 2000
    ..We propose that loss of BIN1 may contribute to breast cancer progression by eliminating a mechanism that restrains the ability of activated MYC to drive cell division inappropriately...
  11. ncbi request reprint Farnesyltransferase inhibitors define a role for RhoB in controlling neoplastic pathophysiology
    G C Prendergast
    The Wistar Institute, Philadelphia, PA, USA
    Histol Histopathol 16:269-75. 2001
    ..Thus, research into the antineoplastic effects of FTIs has led to the identification of a function(s) that is unnecessary for normal cell physiology but crucial for controlling malignant phenotypes...
  12. ncbi request reprint Bin1 mediates apoptosis by c-Myc in transformed primary cells
    J B DuHadaway
    The Wistar Institute, Philadelphia, Pennsylvania 19104, USA
    Cancer Res 61:3151-6. 2001
    ..Loss of Bin1 in human tumors may promote malignant progression in part by helping to stanch the death penalty associated with c-Myc activation...
  13. ncbi request reprint The murine Bin1 gene functions early in myogenesis and defines a new region of synteny between mouse chromosome 18 and human chromosome 2
    N C Mao
    The Wistar Institute, 3601 Spruce Street, Philadelphia, Pennsylvania, 19104, USA
    Genomics 56:51-8. 1999
    ..Since the human gene was mapped previously to chromosome 2q14, the location of Bin1 defines a previously unrecognized region of synteny between human chromosome 2 and mouse chromosome 18...
  14. ncbi request reprint The Bin1 gene localizes to human chromosome 2q14 by PCR analysis of somatic cell hybrids and fluorescence in situ hybridization
    D Negorev
    Medical College of Pennsylvania, Philadelphia, USA
    Genomics 33:329-31. 1996
  15. ncbi request reprint BIN1 is a novel MYC-interacting protein with features of a tumour suppressor
    D Sakamuro
    Wistar Institute, Philadelphia, Pennsylvania 19104, USA
    Nat Genet 14:69-77. 1996
    ..Deficits were functionally significant because ectopic expression of BIN1 inhibited the growth of tumour cells lacking endogenous message. We conclude that BIN1 is an MYC-interacting protein with features of a tumour suppressor...
  16. ncbi request reprint Bin2, a functionally nonredundant member of the BAR adaptor gene family
    K Ge
    The Wistar Institute, Philadelphia, Pennsylvania 19104, USA
    Genomics 67:210-20. 2000
    ..Thus, Bin2 appears to encode a nonredundant function in the BAR adaptor gene family...
  17. ncbi request reprint Loss of heterozygosity and tumor suppressor activity of Bin1 in prostate carcinoma
    K Ge
    The Wistar Institute, Philadelphia, Pennsylvania, USA
    Int J Cancer 86:155-61. 2000
    ..Ectopic expression of Bin1 suppressed the growth of prostate cancer lines in vitro. Our findings support the candidacy of Bin1 as the chromosome 2q prostate tumor suppressor gene...
  18. ncbi request reprint Structural analysis of the human BIN1 gene. Evidence for tissue-specific transcriptional regulation and alternate RNA splicing
    R Wechsler-Reya
    The Wistar Institute, Philadelphia, Pennsylvania 19104, USA
    J Biol Chem 272:31453-8. 1997
    ..This study lays the foundation for genetic and epigenetic investigations into the role of BIN1 in normal and neoplastic cell regulation...
  19. pmc Mechanism for elimination of a tumor suppressor: aberrant splicing of a brain-specific exon causes loss of function of Bin1 in melanoma
    K Ge
    The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104, USA
    Proc Natl Acad Sci U S A 96:9689-94. 1999
    ..Our findings suggest that aberrant splicing of Bin1 may contribute to melanoma progression, and they define a mechanism by which the activity of a tumor suppressor can be eliminated in cells...
  20. pmc A role for the putative tumor suppressor Bin1 in muscle cell differentiation
    R J Wechsler-Reya
    The Wistar Institute, Philadelphia, Pennsylvania 19104, USA
    Mol Cell Biol 18:566-75. 1998
    ..Taken together, the results indicated that Bin1 expression, structure, and localization are tightly regulated during muscle differentiation and suggested that Bin1 plays a functional role in the differentiation process...
  21. ncbi request reprint BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression
    D E Jensen
    The Wistar Institute, Philadelphia, Pennsylvania 19104, USA
    Oncogene 16:1097-112. 1998
    ..BAP1 may be a new tumor suppressor gene which functions in the BRCA1 growth control pathway...
  22. pmc RhoB is dispensable for mouse development, but it modifies susceptibility to tumor formation as well as cell adhesion and growth factor signaling in transformed cells
    A X Liu
    The Wistar Institute, Philadelphia, Pennsylvania, USA
    Mol Cell Biol 21:6906-12. 2001
    ..Our findings suggest that RhoB is a negative regulator of integrin and growth factor signals that are involved in neoplastic transformation and possibly other stress or disease states...
  23. ncbi request reprint A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase
    T Banerjee
    NewLink Genetics Corporation, Ames, IA, USA
    Oncogene 27:2851-7. 2008
    ..The natural product brassinin thus provides the structural basis for a new class of compounds with in vivo anticancer activity that is mediated through the inhibition of IDO...
  24. pmc RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors
    A X Liu
    The Wistar Institute, Philadelphia, Glenolden, Pennsylvania, USA
    Mol Cell Biol 20:6105-13. 2000
    ..Significantly, the apoptotic defect of -/- cells compromised the antitumor efficacy of FTI in xenograft assays. This study offers genetic proof of the hypothesis that RhoB-GG is a crucial mediator of the antineoplastic effects of FTIs...
  25. ncbi request reprint Actin' up: RhoB in cancer and apoptosis
    G C Prendergast
    The DuPont Pharmaceuticals Company, Glenolden Laboratory, Pennsylvania 19004, USA
    Nat Rev Cancer 1:162-8. 2001
    ..Genetic analysis in mice indicates that RhoB is dispensable for normal cell physiology, but that it has a suppressor or negative modifier function in stress-associated processes, including cancer...
  26. pmc Mbh 1: a novel gelsolin/severin-related protein which binds actin in vitro and exhibits nuclear localization in vivo
    G C Prendergast
    Department of Biochemistry, New York University Medical Center, NY 10016
    EMBO J 10:757-66. 1991
    ..The data suggest that Mbh1 may play a role in regulating cytoplasmic and/or nuclear architecture through potential interactions with actin...